<div>
  <ul>
    <li>
      <p>
        Biotechnology company Lusaris Therapeutics has launched from stealth and raised USD 60 million in a Series A funding round led by RA Capital Management with participation from Venrock Healthcare Capital Partners, Deep Track Capital, and Boxer Capital.
      </p>
    </li>
    <li>
      <p>
        The new funds will be used towards advancing the company's lead program, LSR-1019, a 5-Methoxy-N, N-dimethyltryptamine (5-MeO-DMT) based therapy for treatment-resistant depression (TRD) and other severe neuropsychiatric disorders. The company expects to begin Phase 1 trials soon and release topline data by mid-2023.&nbsp;
      </p>
    </li>
    <li>
      <p>
        The company has also entered into a strategic partnership with medical technology company Catalent under which Lusaris obtained an exclusive license to use Catalent&rsquo;s Zydis fast-dissolving tablet technology for its lead drug program, LSR-1019.
      </p>
    </li>
    <li>
      <p>
        Lusaris is focused on developing small molecule neuroplastogen therapeutics to treat neuropsychiatric and neurological disorders. Its lead program LSR-1019 is developed to clear serotonergic psychedelics to treat patients diagnosed with TRD. In addition, the company has two other programs in the pipeline to treat neuropsychiatric and neurological conditions including migraine and cluster headaches.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.biospace.com/article/lusaris-launches-to-turn-toad-venom-into-anti-depression-drug/">
      Bio Space
    </a>
    &nbsp;
  </p>
  <p>
    <a href="https://psychedelicalpha.com/news/lusaris-therapeutics-launches-with-60-million-series-a-financing-to-redefine-the-treatment-of-severe-neuropsychiatric-and-neurological-disorders">
      Psychedelic Alpha
    </a>
    &nbsp;
  </p>
  <p>
  </p>
</div>


All Updates

Lusaris Therapeutics raises USD 60 million in a Series A funding round; launches from stealth